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On September 2013, a 62-year-old man with metastatic adenocarcinoma of the lung
complained tenderness and pain of the ﬁrst terminal phalange of his right hand. The
biopsy conﬁrmed metastatic adenocarcinoma of the lung to the ﬁnger. A single 8-Gy
fraction of palliative radiotherapy was delivered to the patient's right hand. The patient
received magnetic resonance-guided focused ultrasound surgery treatment to the phalange
because he showed few improvement of clinical symptoms and persistence of moderate
pain after radiotherapy. After magnetic resonance-guided focused ultrasound surgery, the
clinical symptoms improved signiﬁcantly. No serious adverse effects were reported and
the patient compliance was very high. Our patient showed improvement of clinical
symptoms after combined treatment. The patient remains in good health conditions.1. Introduction
This case report shows an interesting presentation of meta-
static adenocarcinoma of the lung with no history of tobacco.
Metastases to the distal extremities are a rare presentation of
adenocarcinoma of the lung. Starting treatment early is impor-
tant to relief patients' pain and prevention of morbidity caused
by bone metastases. Radiation therapy represents a successful
and efﬁcient method to palliate pain and prevent comorbidities
caused by bone metastases.
The optimal dose and fraction of prescription for palliative
radiation therapy has been the subject of controversy. In general
radiation therapy practice, a higher radiation dose results in better
tumor control. A single fraction of 8 Gy is as safe and effective as
a multifraction regimen for bone metastases. Magnetic
resonance-guided focused ultrasound surgery (MRgFUS) repre-
sents an effective alternative to palliate pain. The combination ofa single fraction of radiation therapy and MRgFUS appears to be
more effective for pain relief and prevention of comorbidities.
2. Case report
On September 2013, a 62-year-old man with metastatic
adenocarcinoma of the lung complained tenderness and severe
pain [8–9 points to visual analogic scale (VAS)] of the ﬁrst
terminal phalange of his right hand.
The total body computed tomography (CT) scan performed
on September 2013 showed progression in lung, right adrenal
gland and bone metastases of the ﬁrst terminal phalange of his
right hand. The biopsy conﬁrmed metastatic adenocarcinoma of
the lung to the ﬁnger.
The patient was treated with a hypofractionated course of
radiotherapy. The prescribed dose to the target lesion was 8 Gy
delivered through 3D conformal external beam with anterior and
posterior opposed ﬁelds with the use of high-energy photons (6
MV) to the right hand.
Before treatment (CT), planning scan in the supine position
with personalized immobilization systems was performed. CT
acquisitions were analyzed by treatment planning software
(PINNACLE®) to perform target volume contouring and to
evaluate the distribution of isodose. The planning target volume
included the entire tumor mass with a isotropic margin of 2 cm [1].he CC BY-NC-ND license (http://
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few improvements of clinical symptoms after radiotherapy with
persistence of moderate pain (5–6 points to VAS score). The
patient underwent treatment with MRgFUS after radiotherapy.
Prior to treatment of the bone lesion MRgFUS, our patient
underwent unenhanced magnetic resonance (MR) imaging with
contrast material enhancement.
On the day of the scheduled treatment, patients were posi-
tioned on the MRgFUS table with the metastatic lesion centered
above the ultrasound transducer, with positioning and clear ul-
trasound pathway veriﬁed byMR imaging (standard T2-weighted
fat-saturated images). The transducer was housed in a water bath
in the MR table (multielement phased-array transducer, 120 mm
diameter, frequency 1.0–1.5 MHz) and was coupled to the pa-
tient's skin by using a moistened gel pad to eliminate any air in the
ultrasound beam path. A patient-speciﬁc treatment plan was
generated covering the targeted lesion optimizing the number of
sonications, location, and energy levels to avoid damage to non-
targeted tissue. After verifying correct positioning using low-
energy subtherapeutic sonications, treatment began at full en-
ergy, reaching ablation temperatures of 65 C. During each son-
ication, real-time MR thermometry and anatomical images were
acquired. At treatment completion, T1-weighted contrast-
enhanced MR images were acquired [2,3].
MRgFUS was performed with conscious sedation (intrave-
nous midazolam and fentanyl). The patient received the treat-
ment in 1 day. Our patient showed improvement of clinical
symptoms (1–2 points of VAS score).
The patient remains in good health conditions and experi-
enced pain relief and regained the use of his hand.
3. Discussion
Lung cancer is the leading cause of cancer mortality world-
wide, accounting for about 1.3 million deaths each year.
Adenocarcinoma is the most common istological type of non-
small-cell lung cancer (NSCLC) (approximately 40%). Metas-
tasis from NSCLC is common in brain, bones, adrenal glands,
contralateral and liver [4,5].
Bone pain is the most common source of cancer-related pain
in patients suffering from metastatic cancer, especially those
arising in the lung, breast, and prostate [6,7]. The common sites
of bone metastases are the spine, pelvis, and extremities.
The incidence of bone metastases from NSCLC is approxi-
mately 15%–40%. Most occur predominantly in the spine, rib
and pelvis [8]. Metastases to the distal extremities such as our
case are relatively rare.
The consequences of bone metastases include pain, patholog-
ical fractures, spinal cord or nerve root compression or hypercal-
cemia [9]. These events are associatedwith compromised quality of
life of the patients, performance status and independent
functioning and as well may have a shorter overall survival [10].
Starting treatment early is important to relieve patients' pain
and to prevent other comorbidities. The possible treatment
include orthopedic or neurosurgical intervention, radiation
therapy, systemic hormonal therapy or chemotherapy, opioid
and localized nerve blocks.
Radiotherapy is the treatment of choice for localized painful
bone metastases useful in preventing bone fractures [11]. The
appropriate fractionation scheme for the most effective
treatment schedule for bone metastases has been the subject of
debate in the past two decades [12].The various treatment schedule include: 30 Gy in 10 frac-
tions, 20 Gy in 5 fractions, and single fractions of 8 Gy [13].
Based on the evidence from the existing literature there is no
difference in complete or overall pain relief between single
treatment and multifraction palliative radiotherapy for bone
metastases [14]. A single 8 Gy fraction is recommended as the
standard dose-fractionation schedule for the treatment of pain-
ful bone metastases [11].
Depending on the radiation therapy protocol, options for
retreatment may be limited. Alternatively, patients can be treated
with narcotic medications, but those medications may lead to
malaise, mental status changes, nausea, and constipation.
MRgFUS can be used when radiation fails. MR-guided focused
ultrasound is a completely non-invasive procedure, meaning
there is no surgery, no incision, and no blood loss [2].
The patient can return to normal activities within a few days.
Most patients report a decrease in their pain within 1 or 2 days
after MRgFUS. It has been shown that in addition to pain relief,
patients also frequently experience an improved quality of life.
A single fraction of 8 Gy has been shown to be safe, effective
and a low-cost treatment for the palliation of painful metastatic
bone metastases [15]. The addition of MRgFUS to RT can
improve patient symptoms and quality of life.
More studies are needed to evidence the differences in efﬁ-
cacy between different radiation therapy schedules and the
combination of RT and MRgFUS in painful bone metastases
[16].
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